Carvykti (ciltacabtagene autoleucel) — HCPCS Q2056

About Carvykti (ciltacabtagene autoleucel)

Carvykti is the brand name for ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell immunotherapy directed against the B-cell maturation antigen (BCMA), co-developed by Janssen Biotech (a Johnson & Johnson company) and Legend Biotech. This is NOT a CD19 CAR-T — it targets BCMA, expressed on plasma cells and myeloma cells, and is approved exclusively for multiple myeloma. Carvykti is the second BCMA CAR-T to be FDA approved (after Abecma in March 2021) and the first CAR-T approved at 2L+ in multiple myeloma following the April 5, 2024 CARTITUDE-4 approval.

Each Carvykti dose is a patient-specific cellular product distinguished by its unique dual BCMA-binding-domain construct: a single CAR with two camelid-derived VHH single-domain antibodies targeting two distinct epitopes on the BCMA molecule, mounted on a 4-1BB costimulatory domain. This dual-epitope binding is the principal pharmacological feature setting Carvykti apart from Abecma's single-domain BCMA CAR. It drives higher binding avidity, lower antigen-escape risk, and the deepest responses observed in any myeloma CAR-T to date (CARTITUDE-1 ORR 97%). The patient's T cells are collected by leukapheresis, shipped to the Legend Biotech / Janssen manufacturing facility, genetically modified to express the dual-domain BCMA CAR, expanded, cryopreserved, and shipped back to the certified treatment center. Carvykti's vein-to-vein time is approximately 5-7 weeks, the longest of any commercial CAR-T product, and manufacturing capacity has been a recurring constraint historically.

Carvykti carries two FDA-approved indications:

• Adult relapsed/refractory multiple myeloma (4L+) after at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody — approved February 28, 2022 based on the CARTITUDE-1 trial (Berdeja JG et al., Lancet 2021).
• Adult relapsed/refractory multiple myeloma (2L+) after at least one prior line of therapy including a proteasome inhibitor and an IMiD, with disease lenalidomide-refractory — approved April 5, 2024 based on the CARTITUDE-4 trial (San-Miguel J et al., NEJM 2023). This made Carvykti the first CAR-T approved at 2L+ in multiple myeloma, broadening the eligible population significantly versus Abecma's 3L+ position.

Carvykti is billed under HCPCS Q2056 as a single therapeutic dose. The HCPCS descriptor explicitly identifies the BCMA target (distinguishing Q2056 from the CD19 CAR-T Q-codes Q2041, Q2042, Q2053, Q2054). Administration is restricted to FACT-accredited centers certified under the CARVYKTI REMS program, which is independently administered by Janssen separately from BMS's Abecma REMS. Approximate list price (single dose): ~$465,000 USD.

BCMA cellular therapy class — Carvykti vs Abecma vs Tecvayli vs Elrexfio FDA + payer review May 2026

Two BCMA-directed CAR-T products plus two BCMA bispecifics are approved for R/R multiple myeloma. Coding and PA logic are not interchangeable. Carvykti is NOT a CD19 CAR-T.

The 5-stage CAR-T workflow FDA label + REMS verified May 2026

Carvykti billing is fundamentally different from standard drug billing because the encounter spans 8-12 weeks across multiple claims, with extended Parkinsonism/MNT surveillance lasting ≥1 year.

Typical claim cadence

1. Claim A — Apheresis encounter: CMS-1500 or UB-04 with 38206 (or 0540T) + supporting ICD-10 (C90.0x active myeloma). Often paid as outpatient hospital service or office procedure.
2. Claim B — Lymphodepletion encounter(s): J9185 + J9070 with admin CPTs 96413/96415 as appropriate. May span 3 outpatient visits or one short admission.
3. Claim C — CAR-T admission: UB-04 inpatient with ICD-10-PCS procedure (XW033C3 or XW043C3) driving MS-DRG 018. Q2056 line-item is included in the DRG bundle. Or, in outpatient infusion path, UB-04 outpatient with APC payment + Q2056 + 0537T-0541T line items.
4. Claim D — CRS/ICANS readmission (if applicable): Inpatient DRG based on principal manifestation (sepsis, respiratory failure, encephalopathy) with tocilizumab and supportive care billed within the DRG.
5. Claims E+ — Extended Parkinsonism/MNT surveillance (Carvykti-specific): Outpatient neurology E/M codes (99213-99215) with ICD-10 G20.A1/A2 (drug-induced Parkinsonism) or G92.0x (immune effector cell-associated neurotoxicity syndrome). Some payers bundle these into a Carvykti-specific 90-day or 1-year case rate; check the contract before billing line-item.

Dosing & cellular dose math FDA label verified May 2026

Carvykti is one therapeutic dose, calculated to a target 0.5-1.0 x 10^6 CAR-positive viable T cells per kg, with a total dose cap of 100 x 10^6 cells.

Lymphodepletion dosing (Stage 3) — uniform across indications

Per the FDA Carvykti label, the lymphodepletion regimen is the same regardless of indication: fludarabine 30 mg/m^2 IV daily x 3 days (J9185) plus cyclophosphamide 300 mg/m^2 IV daily x 3 days (J9070), days -5 to -3. CAR-T cell infusion proceeds on day 0 (2-4 days after the last lymphodepletion dose). This is the same cyclophosphamide dose used for Abecma and Breyanzi (300 mg/m^2), not the higher 500 mg/m^2 used with Yescarta and Tecartus MCL.

NDC reference FDA NDC Directory + Janssen verified May 2026

Carvykti uses a patient-specific NDC pattern - every patient's dose is uniquely identified by lot under Janssen labeler 57894.

CARVYKTI REMS + FACT accreditation Janssen + FACT verified May 2026

Carvykti is available only through a restricted REMS program because of the boxed warnings for CRS, neurologic toxicities (ICANS, Parkinsonism, Guillain-Barré), HLH/MAS, prolonged cytopenia, IEC-EC (Immune Effector Cell-associated Enterocolitis), and secondary hematological malignancies (MDS, AML, T-cell malignancies).

The CARVYKTI REMS is administered by Janssen Biotech and operates as closed distribution. Three certification layers must all be in place — AND the Carvykti REMS additionally requires documented neurological monitoring infrastructure that no other CAR-T REMS demands:

• Facility certification (Janssen Authorized Treatment Center): the hospital or cellular therapy center must be on the Janssen-maintained list of authorized Carvykti Treatment Centers. Certification requires FACT or FACT-JACIE accreditation for cellular therapy, demonstrated capacity to recognize and manage CRS and ICANS, immediate availability of tocilizumab (Actemra) for IV use, qualified ICU backup, AND — uniquely — documented neurological monitoring infrastructure for delayed Parkinsonism/MNT (baseline neurological exam, serial movement disorder assessments, neurocognitive testing capability, neurology consult availability).
• Healthcare provider certification: prescribing physicians must complete the CARVYKTI REMS training, which includes a Parkinsonism/MNT module not present in other CAR-T REMS programs, and be enrolled.
• Pharmacy / chain-of-custody certification: the receiving pharmacy and cellular therapy lab must verify physician + facility certification before accepting the patient-specific cellular product.

How to enroll / verify

• Web: Janssen maintains the CARVYKTI REMS portal — check the most recent Carvykti Prescribing Information for the current REMS URL and contact. Janssen CarePath (the Carvykti patient hub) can route facility questions to the REMS team.
• FACT accreditation: factwebsite.org — verify accreditation status of any center before referral.
• Documentation: retain REMS enrollment confirmation in the patient chart and on every PA submission. Submit FACT accreditation certificate as a PA attachment. Document the neurological monitoring plan in the PA narrative — some payers explicitly request this for Carvykti.

Administration codes — the multi-stage code set CPT 2026 verified May 2026

Each of the 5 stages has its own administration code family. Map them to the correct claim.

Stage 1 - Apheresis

Stage 3 - Lymphodepletion (chemo admin)

Stage 4 - CAR-T infusion administration set

Stage 5 - CRS / ICANS management AND extended Parkinsonism/MNT surveillance

Acute (day +1 to +28): Tocilizumab (Actemra, HCPCS J3262) is the FDA-approved CRS treatment. Dose for CRS: 8 mg/kg IV (max 800 mg), up to 4 doses. Bill J3262 with appropriate IV infusion admin code (96365). When CRS occurs during the inpatient CAR-T admission, tocilizumab is bundled in MS-DRG 018; when administered outpatient or during a separate readmission, bill J3262 line-item against the relevant ICD-10 (D89.83x for CRS).

Extended Parkinsonism/MNT surveillance (Carvykti-specific): The CARVYKTI REMS requires baseline and serial neurological assessments through ≥ 1 year post-infusion. These encounters are typically captured under outpatient E/M codes (99213-99215 with appropriate prolonged-service codes if applicable) using ICD-10-CM G20.A1 (drug-induced Parkinsonism) or G92.0x (immune effector cell-associated neurotoxicity syndrome) depending on clinical findings. Some commercial payers have a Carvykti-specific bundled-payment arrangement that includes 90-day or 1-year extended neurological surveillance — check the contract before billing E/M encounters as separate line items.

Modifiers CMS + CPT verified May 2026

Modifiers rarely apply to Q2056 itself

Unlike weight-based drug J-codes, the single-dose Q2056 code does not generate JW (drug waste) or JZ (no-waste single-dose container) reporting in most circumstances. The cellular product is one patient-specific therapeutic dose - it is either administered in its entirety to the labeled patient or the manufacturing fails and the product is not infused (in which case Q2056 is not billed). There is no partial-vial waste scenario analogous to small-molecule oncology drugs.

Modifier 25 - same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as a CAR-T-related procedure. Pre-infusion clinical assessment is bundled; a same-day workup for a new complication is separately reportable with 25. This is particularly relevant for Carvykti because extended-window MNT surveillance E/M encounters commonly co-occur with other myeloma maintenance visits.

340B modifiers (JG, TB)

Most CAR-T treatment centers are 340B-covered entities. For 340B-acquired Q2056, follow your MAC's current 340B modifier policy (JG or TB as required). Janssen CAR-T 340B and OPPS/IPPS payment interaction is jurisdiction-specific - verify with your 340B compliance team.

Modifiers on lymphodepletion (Stage 3)

Lymphodepletion uses standard chemotherapy modifier rules - JW on partial-vial waste for fludarabine and cyclophosphamide as needed; JZ when no waste. These follow the standard J9185 and J9070 modifier logic and are unrelated to Q2056 billing.

ICD-10-CM & ICD-10-PCS coding FY2026 verified May 2026

Two coding systems matter: ICD-10-CM for diagnosis (every claim), ICD-10-PCS for the CAR-T procedure (inpatient only - drives MS-DRG 018). Carvykti has unique ICD-10-CM coverage for Parkinsonism/MNT delayed toxicity.

ICD-10-CM diagnoses

ICD-10-PCS procedures (inpatient claims)

Site of care, place of service & DRG/APC mapping FY 2026 IPPS/OPPS verified May 2026

Carvykti is predominantly inpatient under MS-DRG 018; outpatient pathway is emerging but lags behind Breyanzi due to the moderate-to-high CRS rate and extended monitoring requirements.

MS-DRG 018 details

Effective FY 2021, CMS introduced MS-DRG 018 - "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy" as a dedicated CAR-T DRG. Before FY 2021, CAR-T admissions defaulted to MS-DRG 016 (Autologous Bone Marrow Transplant w/ CC/MCC) which significantly under-reimbursed the cellular product cost. MS-DRG 018 is assigned when the ICD-10-PCS principal procedure is XW033C3, XW043C3, or a related new-technology code for autologous CAR-T administration. The relative weight for MS-DRG 018 is among the highest in the IPPS to reflect the high cell product acquisition cost. For Carvykti inpatient admissions, the length of stay typically runs longer than CD19 CAR-T because of the moderate CRS rate (~95% any-grade) and the requirement for acute neurological observation before discharge.

Outpatient CAR-T - APC payment

CMS established a CAR-T outpatient APC pathway; the specific APC number is updated annually in the OPPS Final Rule (APC 9248 has been used historically; verify the current rule). Outpatient billing reports Q2056 as a separately payable line item plus the 0537T-0541T administration set. If CRS develops within 7-30 days, admit to inpatient under a CRS-driven DRG (not back into MS-DRG 018).

Claim form field mapping - 4 claims, one encounter (plus extended surveillance) Janssen + CMS verified May 2026

The Carvykti encounter spans 4 separate index claims plus a surveillance tail unique to Carvykti. Each has its own form, fields, and PA reference.

Claim A — Apheresis (Stage 1)

Claim B — Lymphodepletion (Stage 3)

Claim C — CAR-T infusion (Stage 4)

Claim D — CRS / ICANS readmission (Stage 5 acute, if applicable)

Claims E+ — Extended Parkinsonism/MNT surveillance (Carvykti-specific)

Payer policy snapshot Reviewed May 2026

All major payers require PA, FACT documentation, CARVYKTI REMS enrollment confirmation, indication-specific eligibility documentation, and (uniquely) a neurological monitoring plan for Parkinsonism/MNT surveillance.

NCCN Guidelines

NCCN Multiple Myeloma Guidelines (current version) list Carvykti as Category 1 at 2L+ in lenalidomide-refractory disease (CARTITUDE-4) and at 4L+ in patients exposed to PI + IMiD + anti-CD38 mAb (CARTITUDE-1). NCCN compendium support strengthens coverage arguments and is particularly important for 2L+ Carvykti given the relative newness of the April 2024 FDA approval.

Required PA documentation checklist

• FACT (or FACT-JACIE) accreditation certificate for the treatment center
• CARVYKTI REMS certification letter for the prescribing physician and the facility (NOT the Abecma REMS letter, NOT Yescarta/Tecartus/Breyanzi REMS — manufacturer-specific certifications are independent)
• Prior therapy log: each regimen, dates, IMWG response, reason for discontinuation
• Indication-specific gate documentation:
  • 2L+ MM (CARTITUDE-4): lenalidomide-refractory per IMWG ("progression on or within 60 days of last lenalidomide dose") + prior PI + prior IMiD
  • 4L+ MM (CARTITUDE-1): ≥4 prior lines including PI + IMiD + anti-CD38 mAb
• ECOG performance status (most policies require 0-2)
• Diagnostic pathology / flow cytometry / serum protein electrophoresis confirming BCMA-expressing myeloma
• Imaging / disease burden assessment within recent window (per payer policy, often 30-60 days)
• Cardiac and pulmonary clearance (LVEF, pulmonary function tests as required)
• Baseline neurological assessment documenting absence of pre-existing Parkinsonism / movement disorder + planned MNT surveillance schedule
• Absence of active autoimmune disease requiring systemic immunosuppression

Medicare reimbursement CMS Q2 2026 (live)

Q2056 has a quarterly ASP payment limit; MS-DRG 018 sets the inpatient DRG payment; OPPS APC handles outpatient (rare for Carvykti).

MS-DRG 018 inpatient payment

Inpatient Carvykti claims default to MS-DRG 018 (Chimeric Antigen Receptor Immunotherapy). The DRG relative weight is set annually in the IPPS Final Rule to reflect the high cellular product acquisition cost. MS-DRG 018 bundles the Q2056 drug acquisition into the DRG payment; line-item Q2056 billing on the inpatient claim is informational, not separately payable. Outlier payment may apply when actual costs significantly exceed the DRG payment.

NTAP status (FY 2026)

Carvykti received CMS New Technology Add-on Payment (NTAP) status after FDA approval, with NTAP applying during the standard three-year post-approval window. The 2L+ CARTITUDE-4 approval in April 2024 raised questions about NTAP renewal; verify the current FY 2026 IPPS Final Rule for the up-to-date Carvykti NTAP determination before assuming any add-on payment applies. Even when NTAP is in effect, it is incremental to MS-DRG 018, not a substitute.

OPPS / APC outpatient payment

When Carvykti is administered outpatient (uncommon), CMS pays under the OPPS CAR-T APC pathway with Q2056 as a separately payable line item plus the 0537T-0541T administration set. Verify the current OPPS Final Rule Addendum B for the assigned APC and payment rate.

Patient assistance — MyCARVYKTI & Janssen CarePath Janssen verified May 2026

Carvykti-specific patient support is delivered through the MyCARVYKTI® Patient Support Program (the program publicly named on carvykti.com). Janssen CarePath remains the broader Johnson & Johnson Innovative Medicine hub that backstops MyCARVYKTI for benefits investigation, PA, and appeals across Janssen oncology products.

• MyCARVYKTI® Patient Support Program — the Carvykti-specific program named on the carvykti.com patient site. Connects patients to certified treatment centers, side-effect education, and care navigation.
• Janssen CarePath — benefits investigation, PA support, appeals, case management, and copay assistance for commercially insured patients; the broader J&J Innovative Medicine hub used across Janssen oncology products. Phone-based access; case managers assigned per patient.
• Johnson & Johnson Patient Assistance Foundation (JJPAF) — free product for eligible uninsured / underinsured patients meeting income criteria. Application via CarePath or directly through JJPAF.
• Independent foundations: PAN Foundation, HealthWell Foundation, Leukemia & Lymphoma Society Co-Pay Assistance — multiple myeloma funds open quarterly; check current status before referral.
• Travel grants: Janssen CarePath provides travel assistance for patients > 50-100 miles from a CARVYKTI-certified FACT center. International Myeloma Foundation also offers travel grants.
• Medicare patients: Janssen CarePath provides Medicare navigation but cannot directly subsidize Medicare cost-share per anti-kickback rules. Refer Medicare patients to PAN, HealthWell, and LLS multiple myeloma funds.

Common denial reasons & appeal logic Reviewed May 2026

Carvykti has Carvykti-specific denial patterns reflecting both the REMS structure and the unique Parkinsonism/MNT surveillance requirement.

Carvykti billing FAQ Reviewed May 2026

Is Carvykti a CD19 CAR-T?

No. Carvykti is an anti-BCMA CAR-T, not a CD19 CAR-T. BCMA (B-cell maturation antigen) is expressed on plasma cells and myeloma cells; CD19 is expressed on B lymphocytes and most B-cell lymphomas/leukemias. Carvykti is approved exclusively for multiple myeloma. Do not confuse Q2056 (Carvykti, BCMA, myeloma) with the CD19 CAR-T Q-codes (Q2041 Yescarta, Q2042 Kymriah, Q2053 Tecartus, Q2054 Breyanzi) used for B-cell lymphoma and ALL.

What is the difference between Q2055 (Abecma) and Q2056 (Carvykti)?

Both are BCMA-directed CAR-T products approved for R/R multiple myeloma, but they have separate Q-codes, separate REMS programs, and clinically distinct features. Carvykti (Q2056) uses a unique dual BCMA-binding-domain construct and is approved at 2L+ (lenalidomide-refractory, CARTITUDE-4). Abecma (Q2055) uses a single BCMA-binding domain and is approved at 3L+ only. Carvykti carries the unique Parkinsonism/MNT delayed toxicity that Abecma does not. The chain-of-identity label is the authoritative source for which Q-code to bill.

What is Parkinsonism / MNT and why is it a Carvykti-specific concern?

Movement and Neurocognitive Toxicity (MNT) including Parkinsonism is a delayed neurotoxicity observed primarily with Carvykti among CAR-T products. Onset is typically weeks to months post-infusion (median ~3 months in CARTITUDE-1, with lower incidence in CARTITUDE-4 after risk-mitigation strategies). Features: bradykinesia, tremor, rigidity, micrographia, neurocognitive decline. Incidence in CARTITUDE-1 was approximately 5%; refined patient selection and bridging-therapy approaches in CARTITUDE-4 reduced subsequent rates. The CARVYKTI REMS requires baseline + serial neurological assessments through ≥ 1 year post-infusion. For billing, the extended surveillance window generates outpatient neurology E/M encounters with ICD-10 G20.A1/A2 or G92.0x codes — check the payer contract for bundling vs line-item posture before billing these encounters separately.

What is the Q2056 ASP and how often does it update?

Q2056 has a Medicare ASP+6% payment limit published quarterly by CMS. The Q2 2026 payment limit is $588,494.808 per single dose. ASP files update at the start of each calendar quarter (Q1, Q2, Q3, Q4). Always verify against the live CMS ASP pricing file (medicare-asp.js on this page is live-bound) before finalizing payer estimates or shifting site-of-service decisions on margin.

Can Carvykti be administered outpatient?

Outpatient pathway is policy-emerging for Carvykti but uncommon (single-digit to low-teen percent at qualifying centers vs ~30-50% for Breyanzi). The CRS rate (~95% any-grade, ~5% Grade 3+) and the operational complexity of arranging extended Parkinsonism/MNT monitoring around an outpatient infusion keep most Carvykti cases inpatient under MS-DRG 018. Verify the payer-specific site-of-service policy before assuming outpatient is approved.

Does Carvykti require Janssen CarePath enrollment?

Janssen CarePath is not a strict REMS requirement, but operationally every Carvykti case engages CarePath for benefits investigation, PA support, copay assistance (commercial only), travel grants, and case management. CarePath case managers have direct lines into the CARVYKTI REMS team and payer escalation queues. Engage CarePath at the apheresis-scheduling step, not after PA denial.

What if Q2056 manufacturing fails?

If Janssen/Legend cannot deliver a successful Carvykti product (manufacturing failure rate has historically been low single-digit percent), do not bill Q2056. Bill the apheresis (Claim A) and any lymphodepletion (Claim B) as rendered. Document the manufacturing non-conformance report from Janssen in the chart. Some payers allow repeat apheresis under separate authorization; verify before scheduling.

Source documents Verified May 2026

• FDA Carvykti Prescribing Information (ciltacabtagene autoleucel) — BLA 125746, original approval Feb 28, 2022 (CARTITUDE-1, 4L+ MM); 2L+ MM approval Apr 5, 2024 (CARTITUDE-4). DailyMed setid 7d040b91-3fb8-41db-ba7f-60a36f06e2c2. Most recent label revision: October 16, 2025. Six boxed-warning classes including IEC-EC and Secondary Hematological Malignancies (MDS / AML / T-cell malignancies, the latter per FDA class-wide CAR-T update 2024).
• CMS Q2 2026 ASP Pricing File — Q2056 payment limit $588,494.808 per single dose (live-bound on this page).Updated quarterly.
• FY 2026 IPPS Final Rule — MS-DRG 018 (Chimeric Antigen Receptor Immunotherapy), NTAP determinations for CAR-T products. CMS Federal Register publication.
• CY 2026 OPPS Final Rule — CAR-T APC pathway (APC 9248 historically); Addendum B per quarter.
• NCD 110.24 (CAR-T Cell Therapy) — National Coverage Determination, covers FDA-approved autologous CAR-T including both Carvykti indications.
• NCCN Multiple Myeloma Clinical Practice Guidelines — Carvykti listed Category 1 at 2L+ (post-lenalidomide-refractory, CARTITUDE-4) and Category 1 at 4L+ (post-PI/IMiD/anti-CD38, CARTITUDE-1).
• CARTITUDE-1 — Berdeja JG et al., "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study," Lancet 2021; 398:314-324. DOI 10.1016/S0140-6736(21)00933-8.
• CARTITUDE-4 — San-Miguel J et al., "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma," NEJM 2023; 389:335-347. DOI 10.1056/NEJMoa2303379.
• Carvykti product sites — carvykti.com (patient site, MyCARVYKTI® Patient Support Program) and carvyktihcp.com (HCP site).
• FACT Standards for Cellular Therapy — FACT-JACIE Standards, current revision; factwebsite.org.
• CARVYKTI REMS — Janssen-administered REMS program; current REMS document at the Janssen Carvykti HCP portal.
• Janssen CarePath — patient hub for Carvykti and other Janssen oncology products; benefits investigation, PA, copay (commercial), travel.
• Johnson & Johnson Patient Assistance Foundation (JJPAF) — free product for eligible uninsured / underinsured patients.
• AMA CPT 2026 — Category III codes 0537T-0541T for CAR-T administration; CPT 38206 for autologous leukapheresis.
• IMWG Response Criteria for Multiple Myeloma — for documentation of lenalidomide-refractory status and prior-line responses in PA narratives.